Introduction
For the correction of many inherited or acquired defects of the hematopoietic system, the therapeutic gene must be delivered to cells able both to self-renew and to differentiate into all hematopoietic lineages. As such, these gene therapies must be targeted to the 'right' cell, 'the' human hematopoietic stem cell (HSC), without modifying its properties. Based upon NOD/SCID repopulating cell (SRC) assays, defined as a measure for long-term human repopulating cells, HSC in G0 represent the most primitive, uncommitted hematopoietic progenitors and thus, the preferred targets for gene transfer 1 .
Retroviral vectors, in particular the emerging class of lentiviral vectors (LVs), represent the only means to transduce these cells permanently. LVs can integrate into the chromatin of nondividing cells such as neurons, fibroblasts and hepatocytes [2] [3] [4] [5] , while resting lymphocytes are refractory to LV-mediated gene transfer [6] [7] [8] [9] [10] . We and others have shown that stimulation into the G1b phase of the cell cycle is sufficient to allow productive transduction of quiescent Tcells with lentiviral vectors, while these conditions are insufficient for transduction with murine leukemia virus (MLV)-based retroviral vectors [6] [7] [8] [9] [10] . Whether HIV or the lentiviral vectors can integrate into the genome of a truly quiescent cell, in particular an early progenitor HSC in G0, remains controversial 9, [11] [12] [13] [14] [15] [16] [17] . Compared to their MLV counterparts, LVs do not need extended cytokine stimulation in order to transduce HSCs, avoiding strong cell proliferation, which might lead to loss of stem cell potential 18 . While the LV-mediated transduction of HSCs within the CD34+ cell population, seems possible without cytokine stimulation, a clear boosting effect of strong cytokine cocktails on HSCs transduction was demonstrated [11] [12] [13] [14] 17, [19] [20] [21] . Additionally, in combination with extended cytokine stimulation, protocols often rely on high vector doses per target cell, multiple vector hits, or an increase in virus/target cell contact by centrifugation or use of fibronectin fragments. Such maneuvers are
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To avoid these problems, we refined the surface of LV particles via the display of 'earlyacting cytokines'. We postulated that the new surface-modified LVs would selectively and minimally stimulate HSCs in the CD34+ bulk population during gene transfer with the specific aim to promote high levels of transduction, indispensable for clinical application, in these targets. Thrombopoietin (TPO) and stem cell factor (SCF) were chosen as potent candidates because of their ability to favor the persistence, self-renewal and even expansion of HSCs in an undifferentiated state [22] [23] [24] [25] [26] [27] [28] [29] [30] . Moreover, TPO and SCF act in synergism for these characteristics 31, 32 .
Our results demonstrate that the new LVs, surface-engineered to display 'early-acting cytokine', markedly outperform the current generation of LVs used in the absence and even in the presence of recombinant cytokines, for transduction of the most immature quiescent CD34+ cells, including the critical hematopoietic stem cells, as defined by their capacity to repopulate NOD/SCID mice.
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Results

Functional display of SCF and TPO on HIV-1 derived vectors. To improve gene transfer
into HSCs, we displayed two early acting cytokines, TPO and SCF, on the surface of lentiviral particles. We fused either of two TPO truncated forms (163 and 171 amino-acidlong), previously shown to have a 3-fold higher biological activity than wild type TPO 33, 34 , to the N-terminus of the MLV envelope glycoprotein (gp). These env chimeras are called TPO163SU and TPO171SU, respectively. Additionally, we fused the TPO171 form to the influenza hemaglutinin (HA) glycoprotein (TPOHA). Both fusion partners, the MLV and HA gps incorporate efficiently on LVs 6, 7, 35 . The second cytokine, SCF, was fused to the MLV env gp (SCFSUx) 36 .
We then tested LVs displaying TPO163SU, TPO171SU or TPOHA for functional display of TPO by incubation with BAF3-Mpl cells, which are dependent on rTPO for growth and survival in the absence of IL-3. LVs pseudotyped with either TPO-MLV env chimera (G/163SU and G/171SU) sustained BAF3-Mpl survival ( Fig 1A) . Survival was significantly reduced only at low doses of virus/cell. In contrast, we observed that TPO presentation on LV, by fusion to the HA gp, ensured high BAF3-Mpl survival even at extremely low vector input.
This emphasized the functional display of TPO by TPOHA equivalent to high doses of rTPO ( Fig 1A) . Thus, in all further experiments, the TPOHA chimera was used as the envelope of choice for surface display on LVs. SCF-displaying LVs (G/SCFSUx) efficiently promoted survival of BAF3-cKit cells at high MOIs and a bit less at low vector doses (Fig 1B) . In order to evaluate a potential synergistic effect between SCF and TPO, we produced TPO/SCF-codisplaying vectors using the combination of VSV-G/TPOHA/SCFSUx gps. Clearly, the TPO/SCF-displaying vectors sustained survival of BAF3-Mpl and BAF3-cKit cells to the same extent as their corresponding single cytokine-displaying vectors. As expected, control
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For personal use only. on September 24, 2017. by guest www.bloodjournal.org From decreasing doses of vector (multiplicity of infection (MOI) ranging from 20 to 1), cell survival was determined and compared to that observed following incubation with VSV-G displaying vectors alone or with rTPO (100 ng/ml to 5 ng/ml). G/TPOHA vectors were concentrated (G/TPOHA-conc) by ultracentrifugation and incubations were performed under the same conditions as for non-concentrated TPO-displaying vecctors. (B) BAF3-cKit cells expressing the SCF receptor were incubated with lentiviral vectors presenting SCF at their surface by fusion to the amphotropic MLV glycoprotein (G/SCFSUx) or co-presenting TPO and SCF at their surface. After 72 hr incubation with decreasing doses of virus (MOI ranging from 20 to 1), cell survival was determined and compared to that observed following incubation with VSV-G displaying vectors alone or with rSCF (100 ng to 5 ng/ml). G/SCFSUx vectors were concentrated (G/SCFSUx-conc) by ultracentrifugation and incubations were performed under the same conditions as for non-concentrated SCF-displaying vecctors. (C) Immunoblots of lentiviral vector particles displaying TPOHA, SCFSUx or both chimeric glycoproteins at their surface. Virions were purified over a sucrose-cushion by ultracentrifugation. The upper part of the membrane was stained with antibodies against the influenza HA glycoprotein, the middle section with antibodies against MLV-SU to detect the TPOHA and SCFSUx chimeric envelopes, respectively. The lower part of the membrane was stained with antibodies against HIV-1 capsid to assess equivalent loading of purified vectors. The positions of the chimeric precursor protein (TPOHA), its processed isoform (TPOHA1), the SCFSUx protein and the HIV capsid are indicated. (D) CD34+ CB cells were incubated for 72 hr with the indicated TPO-, SCF-or TPO/SCF-displaying vectors at MOIs of 20 or 4. Survival of the cells was determined by PI staining. As control, CD34+ cells were incubated with vectors displaying VSV-G in the absence (-) or in the presence of cytokines (rTPO = 10 ng/ml; rSCF = 50 ng/ml). Data are shown as means±SD, n=4.
Efficient incorporation of TPOHA and SCFSUx chimera on LV particles was demonstrated by immunoblot detection of highly purified viral pellets with antibodies against MLV gp and HA gp (Fig 1C) . Since lentiviral vectors displaying these chimeric envelope glycoproteins alone showed reduced infectivity, the chimera were incorporated together with the vesicular stomatitis virus G protein (VSV-G) in all experiments described below. This did not affect the incorporation of the TPOHA chimeric envelopes on LV particles and only slightly reduced SCFSUx incorporation. Furthermore, through western-blot analysis of vector particles purified on sucrose-density gradients, we verified that the cytokine-displaying gps were detected in the fraction containing the viral particles and that such association to the viral surface was not disrupted upon co-expression of VSV-G (data not shown). Additionally, G/TPOHA and G/SCFSUx LVs concentrated and purified by ultracentrifugation over a sucrose-cushion could also promote the survival of BAF3-Mpl and BAF3-ckit cells, respectively (G/TPOHA-conc in Fig 1A; G/SCFSUx-conc in Fig 1B) . Altogether, these results indicated that the biological activity of the displayed cytokines was tightly linked to the viral particles.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Finally, we evaluated specific ligand-receptor interactions on the primary targets, immature CD34+ progenitor cells. Of utmost importance was that TPO-, SCF-or TPO/SCF-displaying LVs efficiently protected cord blood (CB) CD34+ cells against apoptosis and this to an extent equivalent to that observed following incubation with high levels of their recombinant cytokine counterparts (Fig 1D) . (Fig 2A) , which were less efficient as expected and reported previously 19 . Since CD34 is often used as a marker of early progenitors, we confirmed by counterstaining that the GFP+ cells retained CD34+ expression. Thus, TPO-, SCF-or TPO/SCF-displaying vectors not only improved survival of CD34+ CB but also promoted high transduction levels of these cells, in a manner similar to VSV-G pseudotyped LVs in the presence of recombinant cytokines (Fig 2B and 2C ).
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For personal use only. on September 24, 2017. by guest www.bloodjournal.org From staining (Fig 4A) . Both CD34+ CB cell populations were incubated with TPO-, SCF-, or TPO/SCF-displaying vectors or VSV-G pseudotyped vectors. In the absence of cytokines, we observed drastic cell death for the G0-sorted cells after incubation with VSV-G LVs (G: 11±1% cell survival), as expected, while TPO-and TPO/SCF-displaying vectors ensured a 7 to 8-fold higher protection of G0 cells (G/TPOHA: 75.0±7.8% cell survival; G/TPOHA/SCFSUx: 88.6±5.6% cell survival; Fig 4B) . SCF-displaying vectors induced survival of G0 CD34+ CB cells to a lower extent (G/SCFSUx: 51.3±13.0 % cell survival; Fig   4B) . This emphasized that quiescent CD34+ CB cells require minimal stimulation by early acting cytokines for survival. The cytokine-displaying vectors even preferentially promoted survival of cells in G0 over those that had entered into cycle (Fig 4B) , which probably depend on other additional cytokines for survival.
Most importantly, TPO-, SCF-and TPO/SCF-displaying vectors transduced more efficiently the G0-sorted cells than the cycling CD34+ cells (Fig 4C) . Indeed, a single exposure with TPO or TPO/SCF-engineered vectors could respectively transduce 4-and 5-fold more CD34+ cells of the resting cell population (G0) than of the cycling population. Thus, the cytokinedisplaying LVs allowed preferential transduction and survival of quiescent CD34 CB cells, a compartment highly enriched in HSCs.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Quiescent cells residing in the G0 phase of the cell cycle (G0 CD34+) have minimal RNA content, as indicated by low PY staining, whereas cells residing into G1b, S, G2+M phase (G1+) have a high RNA content. Sort windows to collect G0 and G1+ cells are shown in the dot blot (A) as R1 and R2, respectively. R1 and R2 were kept well separated to avoid contamination of the two cell categories. The G0 population was checked for purity by 7AAD (DNA)/PY (RNA) staining. The G0/G1a, G1b and SG2M phases are indicated. In (B) and (C) the G0 and G1+ CD34+ populations were transduced for 72 hr with TPO-, SCF-, SCF/TPO -displaying vectors or with VSV-G-pseudotyped vectors. The percentage of CD34+ cell survival is indicated in (B), and the numbers of GFP+ CD34+ marked cells (= number of cells at start of infection (5x10 4 ) x cell expansion x % cell transduction x % cell survival) for the G0 and G1+ populations are shown in (C). Data are shown as means±SD, n=3. (Fig 5) . (Fig 6A and B) .
TPO/SCF-co-displaying vectors allowed transduction of up to 15-fold higher number of progenitors, up to 9-fold higher number of B-cells and up to 6-fold higher number of monocytes as compared to VSV-G speudotyped vectors in the presence of rTPO and rSCF.
Similarly increased transduction levels in progenitors and differentiated cells were found for TPO-and SCF-displaying vectors as compared to unmodified vectors used with either recombinant cytokine (Fig 6A and 6B) . Cell transduction assays performed in the presence of a stronger cytokine cocktail (rTPO+rSCF+rFlk-3) resulted at best in transduction levels equivalent to those obtained with TPO-, SCF-or TPO/SCF-displaying vectors (data not In addition, we found that TPO-displaying vectors resulted in highly superior transduction levels than LVs in the presence of rTPO after lymphoid/myeloid culture (Fig 6B; G (a) incubation with cytokine displaying lentivectors without addition of recombinant cytokines ; (b) incubaton with lentivectors and addition of indicated cytokines (10 ng TPO/ml ; 50 ng SCF/ml ; 100 ng Flk-3/ml). After 72 hr or 24hr of incubation with vector, CD34+ cells were washed and injected by tail vain injection into sublettally irradiated NOD/SCID mice. The animals were sacrificed 7 weeks later and the BM was harvested and assessed for levels of human engraftment and GFP-expressing human cells. Multilineage engrafment was demonstrated by lineages positive markers as indicated and for each lineage the percentage EGFP+ cells were analysed by FACs. Independent experiments were performed with different CD34+ CB samples and different preparations of each vector.
As indicated in Table 1 Table 1 ). Furthermore, a better human cell engraftment was found using cells transduced with the TPO-displaying vectors as compared to unmodified vectors in presence of rTPO, while for the SCF-displaying vectors, the opposite was true.
Detailed flow cytometry analysis revealed that TPO-, SCF-and TPO/SCF-displaying vectors promoted multilineage engraftment (Fig 7A and Table 1 ). Gene marked cells were able to repopulate all hematopoietic lineages in the same manner as unmarked cells, indicating that the differentiation capacity of the transduced cells was not impaired. For TPO-, SCF-and TPO/SCF-displaying LVs, a high level of GFP expression was detected in B-cells (CD45+CD19+), monocytes (CD45+CD14+), immature progenitors (CD45+CD34+) and progenitors/monocytes/granulocytes (CD45+CD13+; Fig 7A and Table 1 ).
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From For Most importantly, we observed a striking preferential transduction of SRCs with the 'earlyacting cytokine'-displaying vectors as compared to VSV-G displaying LVs, even when the latter vectors were used to transduce the CD34+ cells in the presence of recombinant cytokines (see 24 hr transduction in Table 1 and Fig 7A and 7B) . Indeed, TPO-, SCF-and TPO/SCF-displaying vectors could transduce 1.5-to 3-fold more human repopulating cells (hCD45+) and human progenitors (hCD34+) as compared to unmodified LVs in the presence of cytokines (Fig 7B and Table 1 ). For the cytokine-displaying vectors, high levels of GFP+ CD34+ immature cells were detected in the BM of all recipients, in addition to differentiated cells, indicating that immature CD34+ cells had been transduced (Fig 7B and Table 1) .
Overall these data clearly demonstrated that efficient lentiviral gene transfer in primitive hematopoietic progenitors (SRCs), in addition to more differentiated cells, is highly improved by display of TPO and/or SCF on the LV surface as compared to LVs in the presence of rTPO and/or rSCF. To overcome these problems, we designed a novel generation of lentiviral vectors that are surface-engineered for display of "early-acting-cytokines" in order to target and promote gene (Fig 5A and B) . In addition, in long term in vitro cultures, high transduction levels of residual early progenitors were exclusively detected for TPO-, SCF-and TPO/SCF-displaying vectors (Fig 5B) . Moreover, these findings were confirmed by the fact that our cytokine-displaying vectors resulted in up to 3-fold higher transduction of LTC-IC derived colonies as compared to unmodified LVs in the presence of recombinant cytokines (Fig 4) . Theoretically, assuming a maximum of 100-200 gp trimers per viral particle and a ratio of physical to infectious particles of 100-1,000, under our conditions (Table 1 and Fig 7A and 7B ). In addition, we achieved Recently, MLV-derived vectors engineered to display hSCF were described by us 36 and others 43, 44 . While their functional interaction with the c-kit receptor expressed on cell lines could be demonstrated 36, 43, 44 , such vectors only allowed gene delivery to hCD34+ primary cells that were prestimulated with a cocktail of recombinant cytokines, in contrast to the vector described in this report. env gene using the SfiI/NotI backbone fragment of CMVEGFPHA. The SUx mutation 6, 7 , that inhibits furin-mediated cleavage of the MLV glycoprotein, was inserted into the SCFSU construct, resulting in a second chimera, named SCFSUx. All chimeric env gp were expressed in the phCMV-G expression vector backbone 47 .
Production of retroviral vectors. Self-inactivating HIV-1-derived vectors were generated as previously described 7 Control incubations with VSV-G pseudotyped vectors were performed in the absence or presence of rTPO (10 ng/ml) and/ or rSCF (50 ng/ml).
Western blot analysis was performed as previously described 7 .
Sample collection and isolation of CD34+ cells. Umbilical CB samples from full-term pregnancies were collected in sterile tubes containing anti-coagulant. Low-density cells were separated over Ficoll-Hypaque. The living CD34+ cells were gated and in this gate cells in G0 were identified by their minimal RNA content, whereas cells in G1/S/G2+M phase were defined as those with high or maximal PY staining, thus allowing isolation of viable CD34+ cells in G0 or G1/S/G2+M.
The two sorting gates were well separated. After each sorting experiment, the two populations were checked for purity by a Pyronine Y (RNA-)/7AAD (DNA-) staining (Fig 4A) 16, 17, 19 Clonogenic cell assays. Assays for CFCs and LTCIC were performed as described elsewhere 16 . After 14 days of culture in methylcellulose, GFP+ colonies were identified.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From In vitro differentiation assays. We tested lymphoid and myeloid potentials of transduced CD34+ CB cells by culture on MS5 cells in Iscove medium containing 5% FCS or by culture in RPMI on MS5 cells in the presence of rhu-IL2 (5 ng/ml), -IL15 (10 ng/ml) and -SCF (50 ng/ml), 10% human AB serum and 5% FCS for 15 days. The latter cultures were continued for 5 days in the presence of IL-3 (10 ng/ml) and Epo (2U/ml) to assess erythroid maturation. Immunophenotyping by flow cytometry. EGFP expression in the CD34+ CB cell population was analyzed 72 hr post transduction by flow cytometry after immunolabeling with an anti-CD34-PE (BD Pharmingen) antibody. In vitro differentiated CD34+ cells were analyzed for expression of both GFP and differentiation markers, using the following mouse monoclonal antibodies: hCD19-PE, hCD15-PE, hCD14-PE, hGpA-PE (BD Pharmingen), hCD56-and hCD34-PE-Cy5 (Immunotech). Three-color flow cytometry was used to detect GFP+ human cells of various lineages in NOD/SCID bone marrow using anti-hCD45-Cychrome and anti-hCD19-, anti-hCD14-, anti-hCD13 and anti-hCD34-PE antibodies. In all cases, corresponding PE conjugated mouse IgG controls were used.
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